10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2019

or

[  ]  Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Commission File Number: 000-54500

Cell MedX Corp.

(Exact name of registrant as specified in its charter)

Nevada	38-3939625
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

123 W. Nye Ln, Suite 446 Carson City, NV	89706
(Address of principal executive offices)	(Zip code)

(844) 238-2692

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]  No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  Yes [X]  No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  [  ]	Accelerated filer  [  ]
Non-accelerated filer  [  ]	Smaller Reporting Company [X]
	Emerging Growth Company [  ]

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.)  Yes [  ]  No [X]

The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of October 15, 2019 was 55,815,709.

CONTENTS

PART I - FINANCIAL INFORMATION	1
Item 1. Financial Statements	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3. Quantitative and Qualitative Disclosure about Market Risk	17
Item 4. Controls and Procedures	17
PART II - OTHER INFORMATION	18
Item 1. Legal Proceedings	18
Item 1A. Risk Factors	18
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3. Defaults upon Senior Securities	22
Item 4. Mine Safety Disclosures	22
Item 5. Other Information	22
Item 6. Exhibits	22
SIGNATURES	25

ii

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited consolidated interim financial statements of Cell MedX Corp. as at August 31, 2019, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

Operating results for the three months ended August 31, 2019, are not necessarily indicative of the results that can be expected for the year ending May 31, 2020.

As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.

1

CELL MEDX CORP.

CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)

	August 31, 2019		May 31, 2019
	(Unaudited)
ASSETS
Current assets
Cash	$	352,671	$	57,172
Inventory		70,286		73,201
Other current assets		23,858		58,887
Total current assets		446,815		189,260
Equipment		3,497		1,281
Total assets	$	450,312	$	190,541
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	$	866,904	$	734,281
Accrued liabilities		33,035		25,635
Due to related parties		235,314		383,688
Notes and advances payable		162,374		511,754
Unearned revenue		317,324		307,742
Total liabilities		1,614,951		1,963,100
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value,    300,000,000 shares authorized;    48,332,749 and 44,282,749 shares issued    and outstanding at August 31, 2019 and at    May 31, 2019, respectively		48,333		44,283
Additional paid-in capital		5,591,816		5,109,866
Obligation to issue shares		374,148		-
Reserves		14,400		14,400
Accumulated deficit		(7,202,109)		(6,956,822)
Accumulated other comprehensive income		8,773		15,714
Total stockholders' deficit		(1,164,639)		(1,772,559)
Total liabilities and stockholders’ deficit	$	450,312	$	190,541

The accompanying notes are an integral part of these interim consolidated financial statements.

2

CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Three Months Ended
	August 31,
	2019		2018
Revenue
Sales	$	11,343	$	-
Distribution rights		8,958		-
Cost of goods sold		(5,375)		-
Gross margin		14,926		-
Operating expenses
Amortization		268		-
Consulting fees		89,271		63,960
Distribution expenses		16,447		-
General and administrative expenses		86,562		27,242
Research and development costs		60,713		149,734
Total operating expenses		253,261		240,936
Other items
Financing costs		-		(387)
Interest		(6,952)		(2,142)
Net loss		(245,287)		(243,465)
Unrealized foreign exchange translation gain (loss)		(6,941)		869
Comprehensive loss	$	(252,228)	$	(242,596)
Net loss per common share
Basic and diluted	$	(0.01)	$	(0.01)
Weighted average number of shares outstanding
Basic and diluted		47,245,792		44,282,749

The accompanying notes are an integral part of these interim consolidated financial statements.

3

CELL MEDX CORP.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

												Accumulated
				Obligation		Additional						Other
	Common Stock			to Issue		Paid-in				Deficit		Comprehensive
	Shares	Amount		Shares		Capital		Reserves		Accumulated		Income		Total
Balance - May 31, 2018	44,282,749	$	44,283	$	-	$	4,916,201	$	14,400	$	(6,050,841)	$	2,539	$	(1,073,418)
Net loss for the three months ended August 31, 2018	-		-		-		-		-		(243,465)		-		(243,465)
Translation to reporting currency	-		-		-		-		-		-		869		869
Balance - August 31, 2018	44,282,749		44,283		-		4,916,201		14,400		(6,294,306)		3,408		(1,316,014)
Warrants issued for debt	-		-		-		193,665		-		-		-		193,665
Net loss for the nine months ended May 31, 2019	-		-		-		-		-		(662,516)		-		(662,516)
Translation to reporting currency	-		-		-		-		-		-		12,306		12,306
Balance - May 31, 2019	44,282,749		44,283		-		5,109,866		14,400		(6,956,822)		15,714		(1,772,559)
Shares issued for cash	4,050,000		4,050		-		481,950		-		-		-		486,000
Shares to be issued on exercise of warrants	-		-		374,148		-		-		-		-		374,148
Net loss for the three months ended August 31, 2019	-		-		-		-		-		(245,287)		-		(245,287)
Translation to reporting currency	-		-		-		-		-		-		(6,941)		(6,941)
Balance - August 31, 2019	48,332,749	$	48,333	$	374,148	$	5,591,816	$	14,400	$	(7,202,109)	$	8,773	$	(1,164,639)

The accompanying notes are an integral part of these interim consolidated financial statements.

4

CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Three months ended
	August 31,
	2019		2018
Cash flows used in operating activities
Net loss	$	(245,287)	$	(243,465)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable		6,952		2,142
Amortization		268		-
Financing fees - non-cash		-		387
Unrealized foreign exchange		(2,905)		394
Changes in operating assets and liabilities
Inventory		4,215		(3,238)
Other current assets		33,295		1,843
Accounts payable		(3,617)		177,333
Accrued liabilities		7,400		2,900
Unearned revenue		9,236		-
Due to related parties		(13,239)		15,120
Net cash flows used in operating activities		(203,682)		(46,584)
Cash flows used in investing activities
Acquisition of equipment		(2,463)		-
Net cash used in investing activities		(2,463)		-
Cash flows from financing activities
Advances payable		15,000		28,871
Proceeds from notes payable		-		23,029
Proceeds from subscription to shares		486,000		-
Net cash provided by financing activities		501,000		51,900
Effects of foreign currency exchange on cash		644		167
Increase in cash		295,499		5,483
Cash, beginning		57,172		8,200
Cash, ending	$	352,671	$	13,683
Non-cash financing transactions:
Exercise of warrants for debt	$	374,148	$	-

The accompanying notes are an integral part of these interim consolidated financial statements.

5

CELL MEDX CORP.

NOTES TO THE UNAUDITED INTERIM

CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

AUGUST 31, 2019

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness.

Unaudited Interim Financial Statements

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2019, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 6, 2019. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended August 31, 2019, are not necessarily indicative of the results that may be expected for the year ending May 31, 2020.

Going concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of August 31, 2019, the Company has not achieved profitable operations and has accumulated a deficit of $7,202,109. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

Recent accounting pronouncements

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2016-02,“Leases” (“ASU 2016-02”). ASU 2016-02 changes current U.S. GAAP for lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods. Early application is permitted. The Company adopted the ASU 2016-02 on June 1, 2019, and is currently assessing the impact that the adoption will have on future financial statements and disclosures, since as of the date of these financial statements, the Company has no leasing arrangements. However, the Company is evaluating a possible impact ASU 2016-02 may have on the Company’s decision to introduce leasing options for its eBalance devices.

6

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than notes payable to related parties (Note 8) at August 31, 2019 and at May 31, 2019:

	August 31, 2019		May 31, 2019
Due to the former Chief Executive Officer (“CEO”) and director (1)	$	n/a	$	51,746
Due to the CEO		86,400		75,600
Due to the Chief Financial Officer (“CFO”)		25,002		33,507
Due to the Vice President (“VP”), Technology and Operations		37,142		54,999
Due to the former Chief Medical Officer(1)		n/a		81,059
Due to the former VP, Corporate Strategy and major shareholder		86,770		86,777
Due to related parties	$	235,314	$	383,688

(1)The amounts due to former CEO and former Chief Medical Officer have been reclassified to accounts payable, as both persons were not related to the Company as at August 31, 2019. 

The amounts due to related parties are unsecured, due on demand and bear no interest.

During the three-month periods ended August 31, 2019 and 2018, the Company had the following transactions with related parties:

	August 31, 2019		August 31, 2018
Management fees incurred to the CEO	$	10,800	$	10,800
Management fees incurred to the CFO		3,000		3,000
Consulting fees incurred to the VP, Technology and Operations		11,271		11,460
Interest accrued on loans from significant shareholder (Note 8)		6,477		2,048
Total transactions with related parties	$	31,548	$	27,308

NOTE 3 - INVENTORY

As at August 31, 2019, the inventory consisted of eBalance devices held for sale valued at $16,733 (May 31, 2019 - $24,505) and work in progress, that included unfinished eBalance devices and supplies required for manufacturing valued at $53,553 (May 31, 2019 - $48,696).

The cost of eBalance devices used for further research and development and for in-house observational trials are recognized as part of research and development expenses. During the three-month period ended August 31, 2019, the Company recognized $3,712 as cost of eBalance devices used in research and development. The cost of eBalance devices used in marketing and advertising are recognized as part of general and administrative expenses. During the three-month period ended August 31, 2019, the Company recognized $3,712 as cost of eBalance devices used for marketing and advertising purposes.

NOTE 4 - OTHER CURRENT ASSETS

As at August 31, 2019, other current assets consisted of $13,419 in prepaid expenses (May 31, 2019 - $50,331) and $10,439 in receivables associated with GST Cell MedX Canada paid on the taxable supplies (May 31, 2019 - $8,556).

7

NOTE 5 - EQUIPMENT

Changes in the net book value of the equipment at August 31, 2019 and May 31, 2019 are as follows:

	August 31, 2019		May 31, 2019
Book value, beginning of the period	$	1,281	$	-
Changes during the period		2,463		1,915
Amortization		(268)		(580)
Foreign exchange		21		(54)
Book value, end of the period	$	3,497	$	1,281

NOTE 6 - UNEARNED REVENUE

Changes to the unearned revenue as at August 31, 2019 and May 31, 2019:

	August 31, 2019		May 31, 2019
Unearned revenue, beginning of the period	$	307,742	$	51,585
Deposits to distribution rights		25,000		250,000
Security deposits received from/(refunded to) customers		(2,269)		6,806
Security deposits recognized in sales		(4,537)		-
Non-refundable deposit on distribution rights		(8,958)		-
Foreign exchange		346		(649)
Unearned revenue, end of the period	$	317,324	$	307,742

During the three-month period ended August 31, 2019, the Company entered into a letter of intent for the wholesale distribution rights to all Mainlined China, not including Hong Kong (the “LOI”). As part of the LOI the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000. The LOI’s term is 240 days, in which for the first 120 days the Distributor will be permitted to test the eBalance devices (the “Testing Period”). During the Testing Period, the Company agreed not to enter into any agreements for the wholesale rights to Mainland China.

The Company amortizes the non-refundable deposit received from the Distributor on a straight-line basis over the full length of the LOI. As at August 31, 2019, $8,958 were recorded as revenue from distribution rights (Note 7).

NOTE 7 - REVENUE

During the three-month period ended August 31, 2019, the Company’s revenue consisted of sales of its eBalance devices to end-users and sale of rights to the wholesale distribution of eBalance devices.  Following are the details of revenue and associated costs:

	Three months ended August 31, 2019
Sales of eBalance devices	$	11,343
Cost of eBalance devices		(4,052)
Royalty payable		(1,323)
Distribution rights (Note 6)		8,958
Gross margin	$	14,926

8

NOTE 8 - NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at August 31, 2019 and May 31, 2019:

As at August 31, 2019
Principal Outstanding		Interest Rate per Annum		Accrued Interest(5)		Total Book Value
$	29,468	6%	Non-convertible(1)	$	2,103	$	31,571
	6,870	6%	Related party(2)		4		6,874
	35,606	6%	Related party(2),(3)		17		35,623
	88,306	0%	Advances(4)		--		88,306
$	160,250			$	2,124	$	162,374
As at May 31, 2019
Principal Outstanding		Interest Rate per Annum		Accrued Interest(5)		Total Book Value
$	29,065	6%	Non-convertible(1)	$	1,613	$	30,678
	114,027	0%-12%	Related party(2)		12,533		126,560
	275,000	6%	Related party(2),(3)		6,468		281,468
	73,048	0%	Advances(4)		--		73,048
$	491,140			$	20,614	$	511,754

(1) Loans Payable

As at August 31, 2019, the Company owed a total of $31,571 (2019 - $30,678) under two separate loan agreements. Both loans bear interest at 6% per annum compounded monthly, are unsecured, and payable on demand.

(2) Related Party Loans Payable

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 2,482,960 warrants to acquire 2,482,960 shares of the Company granted in consideration for the funds Mr. Jeffs advanced to the Company during its fiscal 2019 and 2018 years.  To exercise the warrants, Mr. Jeffs chose to apply $124,148, the Company owed under the demand notes payable against the purchase price of the shares (Note 9). The exercise price was first applied to $15,051 (CAD$20,019) in interest accrued on the notes payable, with the remaining $109,097 (CAD$145,110) applied to principal. The shares were issued on September 9, 2019. As at August 31, 2019, the Company owed Mr. Jeffs $6,874 under the remaining note payable, which continues to accumulate interest at 6% per annum compounded monthly.

(3) Unsecured Line of Credit with Related Party

On August 28, 2019, Mr. Jeffs exercised 5,000,000 warrants to acquire 5,000,000 shares of the Company granted to Mr. Jeffs in consideration for an unsecured line of credit of up to $250,000 (the “Credit Line”) dated for reference December 27, 2018.  To exercise the warrant, Mr. Jeffs chose to apply $250,000, the Company owed under the Credit Line against the purchase price of the shares (Note 9). The exercise price was first applied to $10,606 in interest accrued on the balance due under the Credit Line, $25,000 was applied towards the Credit Line set-up fee, and the remaining $214,394 was applied to principal. The shares were issued on September 9, 2019. As at August 31, 2019, the Company owed Mr. Jeffs $35,623 under the Credit Line, which continues to accumulate interest at 6% per annum compounded monthly.

(4) Advances Payable

During the three-month period ended August 31, 2019, the Company borrowed $15,000. The advances are non-interest bearing, unsecured and payable on demand. As at August 31, 2019, a total of $88,306 (2019 - $73,048) was due and payable on account of the advances.

(5) Interest Expense

During the three-month period ended August 31, 2019, the Company recorded $ 6,952 (2019 - $2,142) in interest expense associated with its liabilities under the notes and advances payable, of which $2,321 (2019 - $2,048) was accrued on the loans received from Mr. Jeffs, and $4,156 (2019 - $Nil) in interest accrued on the Line of Credit.

9

NOTE 9 - SHARE CAPITAL

On May 30, 2019, the Company announced a non-brokered private placement offering (the “2019 Offering”) set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of up to $750,000. Each Unit sold under the 2019 Offering was to consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant. Each Warrant will be exercisable into one share of the Company’s common stock at $0.20 per share.

On June 24, 2019, the Company closed the first tranche of its 2019 Offering by issuing 3,950,000 Units for total gross proceeds of $474,000. On July 22, 2019 the Company closed the second tranche of the 2019 Offering by issuing 100,000 Units for total gross proceeds of $12,000

Options

The changes in the number of stock options outstanding during the three-month period ended August 31, 2019 and for the year ended May 31, 2019 are as follows:

	Three months ended August 31, 2019			Year ended May 31, 2019
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	7,050,000	$	0.24	9,450,000	$	0.35
Options cancelled	--	$	n/a	(2,400,000)	$	0.67
Options outstanding, ending	7,050,000	$	0.24	7,050,000	$	0.24

Details of options outstanding and exercisable as at August 31, 2019, are as follows:

Exercise price	Grant date	Number of options Outstanding and exercisable
$0.05	November 25, 2014	2,500,000
$0.35	August 5, 2015	2,500,000
$0.35	August 24, 2017	2,050,000
$0.24		7,050,000

At August 31, 2019, the weighted average remaining contractual life of the stock options outstanding was 1.55 years.

Warrants

The changes in the number of warrants outstanding during the three-month period ended August 31, 2019 and for the year ended May 31, 2019 are as follows:

	Three months ended August 31, 2019	Year ended May 31, 2019
Warrants outstanding, beginning	20,297,565	12,814,605
Warrants issued	4,050,000	7,482,960
Warrants exercised	(7,482,960)	--
Warrants outstanding, ending	16,864,605	20,297,565

10

Details of warrants outstanding as at August 31, 2019, are as follows:

Exercise price	Grant Date	Number of warrants exercisable
$0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021	March 3, 2016	2,000,000
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021	October 12, 2016	9,094,605
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020	October 12, 2017	1,480,000
$1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021	February 7, 2018	240,000
$0.20 expiring on June 24, 2021	June 24, 2019	3,950,000
$0.20 expiring on July 22, 2021	July 22, 2019	100,000
		16,864,605

At August 31, 2019, the weighted average life and exercise price of the warrants was 1.86 years and $0.76, respectively.

NOTE 10 - SUBSEQUENT EVENTS

Subsequent to August 31, 2019, the Company received $167,150 under convertible notes payable which bear interest at 6% per annum compounded monthly. At the discretion of the lenders, the balance of the note payable may be converted to shares of the Company’s common stock at the price of then current private placement financing.

Subsequent to August 31, 2019, the Company paid $42,500 for promotional and investor relations activities aimed to increase awareness about the Company within the investment community.

11

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.

The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2019, filed with the United States Securities and Exchange Commission (the “SEC”) on September 6, 2019.

Overview

We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our current business direction.

On November 25, 2014, we completed the acquisition of a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments (the “eBalance Technology”).  With our acquisition of the eBalance Technology, we have shifted our business direction to the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia, in anticipation of increased business activity in Canada. As of the day of this Quarterly Report on Form 10-Q the Subsidiary is engaged in manufacturing and further development of eBalance Technology.

Recent Corporate Developments

The following corporate developments occurred during the quarter ended August 31, 2019, and up to the date of the filing of this report:

Private Placement Financing

On May 30, 2019, the Company announced that it had arranged a non-brokered private placement offering (the “Offering”) set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of $750,000. Each Unit sold under the Offering was to consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant and exercisable into one share of the Company’s common stock at $0.20 per share.

The Units were to be issued pursuant to the provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act. The Units to U.S. Persons were to be issued pursuant to the provisions of Rule 506(b) of Regulation D of the Act who qualify as “accredited investors” as that term is defined under Regulation D of the Act.

On June 24, 2019, the Company closed the first tranche of the Offering by issuing 3,950,000 Units for total gross proceeds of $474,000. On July 22, 2019, the Company closed the second tranche of the Offering by issuing 100,000 Units for total gross proceeds of $12,000. The Units were issued pursuant to the provisions of Regulation S of the Act to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act.

The Company closed the Offering on September 6, 2019.

12

Exercise of Warrants

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised a total of 7,482,960 warrants to acquire 7,482,960 shares the Company granted to Mr. Jeffs in consideration for the Line of Credit and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements. To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the Line of Credit and the notes payable against the purchase price of the shares. The shares were issued on September 9, 2019.

Engagement of Think Ink Marketing for Investor Outreach Program

On June 20, 2019, the Company entered into public relations services agreement with Think Ink Marketing Data & Email Services, Inc., a California-based marketing firm established in 1991 that provides its customers with a complete range of marketing services (“Think Ink”), to develop an investor outreach program. The Company agreed to a minimum payment of $25,000, applied on pay-per-click basis to traffic generated by adds/marketing material.

Commercial Sales Activity

In Fiscal 2019, the Company received all required electrical and safety certifications for its eBalance device, which allowed the Company to commence commercialization of its eBalance devices in Canada as non-medical wellness devices. To begin establishing the customer base, the Company entered into two separate agreements with two independent consultants, who agreed to work with the Company as its sales representatives (the “Sales Representatives”) and to introduce the eBalance devices to various wellness clinics in British Columbia, Canada. Based on the agreements, the Sales Representatives will receive CAD$350 commission fee on each device they sell. In order to establish the initial customer base, the Company agreed to a set monthly fee of CAD$5,000 payable to each Sales Person for an initial three-month term.

Results of Operations for the Three Months ended August 31, 2019 and 2018

Our operating results for the three-month periods ended August 31, 2019 and 2018, and the changes in the operating results between those periods are summarized in the table below.

	Three Months Ended
	August 31, 2019		August 31, 2018		Percentage Increase / (Decrease)
Sales	$	11,343	$	-	n/a
Distribution rights		8,958		-	n/a
Cost of goods		(5,375)		-	n/a
Gross margin		14,926		-	n/a
Operating expenses
Amortization		268		-	n/a
Consulting fees		89,271		63,960	39.6%
Distribution expenses		16,447		-	n/a
General and administrative expenses		86,562		27,242	217.8%
Research and development costs		60,713		149,734	(59.5)%
Total operating expenses		253,261		240,936	5.1%
Financing costs		-		387	(100.0)%
Interest		6,952		2,142	224.6%
Net loss	$	245,287	$	243,465	0.7%

Revenues

During the three-month period ended August 31, 2019, we recognized $11,343 (CAD$15,000) in revenue, which consisted of sales of our eBalance wellness devices to end-users. The cost attributed to this revenue was $5,375 and consisted of $4,052 in manufacturing costs of eBalance devices, and $1,323 in royalties we accrued on the sale of each device.

13

On June 6, 2019, we entered into a letter of intent for the wholesale distribution rights to all Mainlined China, not including Hong Kong (the “LOI”). As part of the LOI the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000, of which $8,958 we recorded as revenue from distribution rights for the three-month period ended August 31, 2019.

We did not generate any revenue during the three-month period ended August 31, 2018.

As of the date of this report on Form 10-Q, we continue research and further development of our eBalance Technology and devices based on this technology, we are also working towards certifying our device with Health Canada as Class II medical device, and compiling a required documentation for a 510(K) premarket submission with FDA, which allows to demonstrate that the eBalance device is at least as safe and effective as a legally marketed device available on the market, which, if the submission is approved, will allow us to start our commercial activity in the USA. Until we receive Health Canada and FDA approvals, we will only be able to sell our devices as wellness devices in Canada, which will limit our potential revenue in a foreseeable future due to a smaller market share.

Operating Expenses

During the three-month period ended August 31, 2019, our operating expenses increased by 5.1% from $240,936 incurred during the three months ended August 31, 2018, to $253,261 incurred during the three months ended August 31, 2019. The most significant changes were as follows:

·During the three-month period ended August 31, 2019, our consulting fees increased by $25,311, from $63,960 we incurred during the three-month period ended August 31, 2018, to $89,271 we incurred during the three months ended August 31, 2019. Larger consulting fees during the three-month period ended August 31, 2019, were associated with $25,000 we paid for consultation on setting up our distribution channels in China. 

·Our research and development fees for the three-month period ended August 31, 2019, decreased by $89,021, from $149,734 we incurred during the three-month period ended August 31, 2018, to $60,713 we incurred during the three months ended August 31, 2019. The higher research and development fees during the three-month period ended August 31, 2018, resulted mainly form $140,460 (CAD$185,000) we incurred to Western Robotics Ltd., whom we engaged to assist us with enhancement and re-designing of our eBalance Pro wellness devices. During the three months ended August 31, 2019, our improvements were mainly associated with integration of automated billing module and smaller updates and upgrades to the eBalance device. 

·During the three-month period ended August 31, 2019, we incurred $16,447 in distribution expenses we paid or accrued to our sales representatives, who began working on distribution of our eBalance devices in British Columbia, Canada (2019 - $Nil). Based on our agreements with the Sales Representatives, we agreed to pay CAD$350 as commission for each eBalance device they sell. In order to allow our Sales Representatives to establish their customer base, we agreed to a monthly fee of CAD$5,000 payable to each Sales Representative for an initial term of three months. 

·Our general and administrative fees for the three-month period ended August 31, 2019, increased by $59,320, or 217.8%, from $27,242 we incurred during the three-month period ended August 31, 2018, to $86,562 we incurred during the three months ended August 31, 2019. The largest factor that contributed to this change was associated with our expenditures on corporate communication per our services agreement with Think Ink Marketing, which resulted in $56,338 we recorded during the three-month period ended August 31, 2019, as compared to $486 we incurred during the three-month period ended August 31, 2018. Other factors that affected our general and administrative fees were associated with marketing and advertising fees, which increased by $4,191 as apposed to not having any expenses of this type during the comparative period ended August 31, 2018, and a $4,000 increase to our accounting and audit fees, which increased from $3,000 during the three-month period ended August 31, 2018, to $7,000 during the three-month period ended August 31, 2019. These increases were offset by $1,966 decrease in travel and entertainment fees, which amounted to $871 during the three months ended August 31, 2019, and $3,552 decrease in foreign exchange, which resulted in $3,308 gain for the three-month period ended August 31, 2019, as opposed to $244 loss for the three months ended August 31, 2018. 

14

Other Items

During the three-month period ended August 31, 2019, we accrued $6,952 (2019 - $2,142) in interest associated with the outstanding notes payable. Of this interest, $2,321 (2019 - $2,048) was accrued on the notes payable we issued to Mr. Jeffs, our major shareholder, and $4,156 (2019 - $Nil) was accrued on the Line of Credit with Mr. Jeffs. During the three-month period ended August 31, 2018, we accrued $387 in financing fees payable to Mr. Jeffs as part of notes payable we issued to Mr. Jeffs.

Liquidity and Capital Resources

Working Capital

	As at August 31, 2019		As at May 31, 2019		Percentage Change
Current assets	$	446,815	$	189,260	136.1%
Current liabilities		1,614,951		1,963,100	(17.7)%
Working capital deficit	$	(1,168,136)	$	(1,773,840)	(34.1)%

As of August 31, 2019, we had a cash balance of $352,671, a working capital deficit of $1,168,136 and cash flows used in operations of $203,682 for the period then ended. During the three-month period ended August 31, 2019, we funded our operations with $486,000 received on subscription to the shares of our common stock, and $15,000 we borrowed under short-term advances.

We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended August 31, 2019. The amount of cash we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under the outstanding notes and advances payable, or to service our other debt obligations.  If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Cash Flows

	Three months ended August 31,
	2019		2018
Cash flows used in operating activities	$	(203,682)	$	(46,584)
Cash flows used in investing activities		(2,463)		-
Cash flows provided by financing activities		501,000		51,900
Effects of foreign currency exchange on cash		644		167
Net increase in cash during the period	$	295,499	$	5,483

Net Cash Used in Operating Activities

Net cash used in operating activities during the three months ended August 31, 2019, was $203,682. This cash was primarily used to cover our cash operating expenses of $240,972 and to decrease our accounts payable and amounts due to related parties by $3,617 and $13,239, respectively. These uses of cash were offset by $4,215 and $33,295 decreases in our inventory and other current assets, respectively, and by increases in our accrued liabilities and unearned revenue of $7,400 and $9,236 respectively.

Net cash used in operating activities during the three months ended August 31, 2018, was $46,584. This cash was primarily used to cover our cash operating expenses of $240,542 and to increase our inventory by $3,238. These uses of cash were offset by increases in our accounts payable and amounts due to related parties of $177,333 and $15,120, respectively, by $2,900 increase to our accrued liabilities and $1,843 decrease in other current assets.

15

Non-cash transactions

During the three-month period ended August 31, 2019, our net loss was affected by the following expenses that did not have any impact on cash used in operations:

·$6,952 (2019 - $2,142) in interest we accrued on the outstanding notes payable. Of this interest, $2,321 (2019 - $2,048) was accrued on the notes payable we issued to Mr. Jeffs, and $4,156 (2019 - $Nil) was accrued on the $250,000 line of credit provided to us by Mr. Jeffs; 

·$Nil (2019 - $387) in financing fees associated with notes payable we issued to Mr. Jeffs; and 

·$2,905 gain (2019 - $394 loss) in unrealized foreign exchange, which resulted from fluctuations of Canadian dollar denominated transactions. 

·During the three-month period ended August 31, 2019, we recorded $268 in amortization on the equipment we acquired for our manufacturing operations and for our office. 

Net Cash Provided by Financing Activities

During the three-month period ended August 31, 2019, we were advanced a total of $15,000 which were payable on demand. In addition to the advances, we issued 4,050,000 units of our common stock for total proceeds of $486,000. We did not incur any share-issuance costs associated with the Offering.

During the thee-month period ended August 31, 2018, we borrowed a total of $23,029 (CAD$30,000) from Mr. Jeffs. Of this amount CAD$20,000 in principal bore interest at 12% per annum, compounded monthly, as unsecured and payable on demand; and CAD$10,000 was advanced as a non-interest bearing short-term loan, which was payable within 14 days from the grant. We did not pay this loan when due, and therefore during the three-month period ended August 31, 2018, it was payable on demand. In addition to the loans with Mr. Jeffs, we received an additional $28,871 in non-interest bearing advances payable on demand.

Net Cash Used in Investing Activities

During the three-month period ended August 31, 2019, we purchased three laptop computers for $2,463. We did not have any investing activities during the three-month period ended August 31, 2018.

Going Concern

The notes to our unaudited interim consolidated financial statements at August 31, 2019, disclose our uncertain ability to continue as a going concern. Our current business operations are in an early development stage and as such, we were able to generate only minimal revenue from the operations. Our research and development as well as marketing plans for the near future will require large capital expenditures, which we are planning to mitigate through equity or debt financing, or combination of both. In addition, we anticipate continuing to require upfront deposits from our potential distributors, once additional geographical distribution zones are determined.

We have accumulated a deficit of $7,202,109 since inception and increased sales will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our audited consolidated financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.

Off-Balance Sheet Arrangements

None.

16

Critical Accounting Policies

An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.

Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure

None.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

None

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of August 31, 2019. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended August 31, 2019, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

17

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There is a high degree of risk associated with investing in our securities.  Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.

The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.

Risks Associated with our Company and our Industry

We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments.  Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.

The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.

We are subject to numerous governmental regulations which can increase our costs of developing our eBalance Technology and products based on this technology.

Our products may be subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.

Changes in the health care regulatory environment may adversely affect our business.

A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.

18

Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.

Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.

Our research and development efforts may not result in the development of commercially successful products based on our eBalance Technology, which may hinder our profitability and future growth.

Our eBalance Technology is currently in the research and development stage as are our planned products incorporating this technology.  In order to develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.

Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.

Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.

New products and technological advances by our competitors may negatively affect our results of operations.

Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.

Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.

Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.

19

Inability to attract and maintain key personnel may cause our business to fail.

Success depends on the acquisition of key personnel. We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants.  If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.

To date we have generated only minimal revenues. If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.

To date we have generated only minimal revenues. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing.  We have a very limited operating history and thus our progress as well as potential future success cannot be reasonably estimated.  Success has yet to be proven and financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance Technology, of which there is no assurance. We continue to face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties.  Since inception, we have accumulated deficit of $7,202,109 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.

We need to acquire additional financing or our business will fail.

We must obtain additional capital or our business will fail. In order to continue development of our eBalance Technology and to successfully complete clinical trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on.  We currently have no arrangements for additional financing.  We may also have to borrow large sums of money that require substantial capital and interest payments.

Risks related to our stock

We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.

Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue.  However there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.

There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.

Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.

Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.

Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations.  Liquidity may be low despite there being a market, making it difficult to get a return on the investment.  The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.

20

Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.

Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:

·contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; 

·contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws; 

·contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; 

·contains a toll-free telephone number for inquiries on disciplinary actions; 

·defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and 

·contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation. 

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

We have not paid nor anticipate paying cash dividends on our common stock.

We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history.  The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:

(a)we would not be able to pay our debts as they become due in the usual course of business; or 

(b)except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution. 

We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business.

21

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 24, 2019, the Company closed the first tranche of its private placement offering (the “Offering”) by issuing 3,950,000 Units for total gross proceeds of $474,000. On July 22, 2019, the Company closed the second tranche of the Offering by issuing 100,000 Units for total gross proceeds of $12,000. Each Unit sold under the Offering consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant and exercisable into one share of the Company’s common stock at $0.20 per share. The Units were issued pursuant to the provisions of Regulation S of the Act to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act.

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 7,482,960 warrants to acquire 7,482,960 shares the Company granted to Mr. Jeffs in consideration for the Line of Credit and in recognition of $124,128 previously advanced to the Company by Mr. Jeffs in series of separate loan agreements. To exercise the warrants, Mr. Jeffs chose to apply $374,148, the Company owed under the Line of Credit and notes payable against the purchase price of the shares. The shares were issued on September 9, 2019. The Units were issued pursuant to the provisions of Regulation S of the Act to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit
Number	Description of Document
3.1	Articles of Incorporation (2)
3.2	Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(5)
3.3	Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(5)
3.4	Bylaws (1)
4.1	Specimen Stock Certificate (1)
10.4	Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6)
10.5	First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(7)
10.6	Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(8)
10.7	Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)
10.8	Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves.(9)
10.9	First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)
10.10	First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves. (9)
10.11	Management Consulting Agreement dated January 13, 2015 among Cell MedX Corp., and Dr. John Sanderson, MD.(10)
10.12	Stock Option Agreement dated December 12, 2014 among Cell MedX Corp. and Dr. John Sanderson, MD.(10)
10.13	Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(11)

22

Exhibit
Number	Description of Document
10.14	eBalance Prototype Development Agreement dated October 1, 2015 among Cell MedX Corp., and Claudio Tassi.(12)
10.15	Non-binding Letter of Intent dated December 4, 2015 to Enter into Development Agreement and License Agreement among Cell MedX Corp., Claudio Tassi, and Bioformed Aesthetic S.L.(13)
10.16	Loan Agreement and Note Payable dated February 4, 2016, among Cell MedX Corp., and Tradex Capital Corp.
10.17	Loan Agreement and Note Payable dated March 2, 2016, among Cell MedX Corp., and Tradex Capital Corp.
10.18	Loan Agreement dated March 3, 2016 between Richard Norman Jeffs and Cell MedX Corp.(14)
10.19	Loan Agreement and Note Payable dated March 10, 2016, among Cell MedX Corp., and Tradex Capital Corp.(15)
10.20	Loan Agreement and Note Payable dated March 30, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)
10.21	Loan Agreement and Note Payable dated March 31, 2016 among Cell MedX Corp., and Richard N. Jeffs.(16)
10.22	Loan Agreement and Note Payable dated April 29, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.23	Loan Agreement and Note Payable dated June 1, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)
10.24	Loan Agreement and Note Payable dated June 2, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.25	Loan Agreement and Note Payable dated June 29, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)
10.26	Loan Agreement and Note Payable dated June 30, 2016, among Cell MedX Corp., and Richard N. Jeffs. (16)
10.27	Loan Agreement and Note Payable dated August 8, 2016, among Cell MedX Corp., and Richard N. Jeffs.(16)
10.28	Loan Agreement and Note Payable dated August 22, 2016, among Cell MedX Corp., and Tradex Capital Corp.(16)
10.29	Letter Agreement dated September 26, 2016, between Jean Arnett, Brad Hargreaves and Cell MedX Corp.(17)
10.30	Loan Agreement and Note Payable dated January 6, 2017, among Cell MedX Corp., and Richard N. Jeffs.(18)
10.31	Loan Agreement and Note Payable dated February 7, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19)
10.32	Loan Agreement and Note Payable dated February 27, 2017, among Cell MedX Corp., and Richard N. Jeffs.(19)
10.33	Loan Agreement and Note Payable dated January 11, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)
10.34	Loan Agreement and Note Payable dated January 13, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)
10.35	Loan Agreement and Note Payable dated February 14, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)
10.36	Loan Agreement and Note Payable dated March 8, 2017, among Cell MedX Corp., and Tradex Capital Corp.(19)
10.37	Loan Agreement and Note Payable dated April 18, 2017, among Cell MedX Corp., and Perla Capital Inc.(19)
10.38	Loan Agreement and Note Payable dated May 5, 2017, among Cell MedX Corp., and Tradex Capital Corp.(19)
10.39	Loan Agreement and Note Payable dated July 12, 2017, among Cell MedX Corp., and Richard N. Jeffs. (20)
10.40	Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina(20)
10.41	Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp.(20)
10.42	Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco (20)
10.43	Product Development Agreement for eBalance dated October 16, 2017, among Cell MedX Corp. and Western Robotics Ltd.(21)
10.44	Management Consulting Agreement between Dr. Terrance Owen and Cell MedX Corp. dated effective as of December 1,  2017.(22)
10.45	Loan Agreement and Note Payable dated April 5, 2018, among Cell MedX Corp., and Richard N. Jeffs.

23

Exhibit
Number	Description of Document
10.46	Loan Agreement and Note Payable dated May 8, 2018, among Cell MedX Corp., and Richard N. Jeffs.
10.47	Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018.
10.48	Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs, dated for reference September 6, 2018.
10.49	Letter of Intent between the Company and Live Current Media, Inc. dated for reference September 10, 2018.
10.50	Loan Agreement and Note Payable dated September 13, 2018, among Cell MedX Corp., and Tradex Capital Corp. (23)
10.51	Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.(24)
10.52	Distribution Agreement between Cell MedX Corp. and Live Current Media, Inc., dated for reference March 21, 2019. (25)
14.1	Code of Ethics(3)
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following materials from this Quarterly Report on Form 10-Q for the three-month period ended August 31, 2019 and 2018 formatted in XBRL (extensible Business Reporting Language):
	(1) Consolidated Balance Sheets at August 31, 2019 (unaudited) and as at May 31, 2019.
	(2) Unaudited Condensed Interim Consolidated Statements of Operations for the three-month periods ended August 31, 2019 and 2018.
	(3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit as at August 31, 2019.
	(4) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the three-month periods ended August 31, 2019 and 2018.

(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010 

(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010 

(3)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with SEC on August 26, 2014 

(4)Reserved 

(5)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014 

(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014 

(7)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014 

(8)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014 

(9)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2014 

(10)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 13, 2015 

(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015 

(12)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2016 

(13)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 15, 2015 

(14)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016 

(15)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2016 

(16)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2016 

(17)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2016 

(18)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2017 

(19)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 29, 2017 

(20)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017 

(21)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 16, 2018 

(22)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on December 5, 2017. 

(23)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2019 

(24)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018 

(25)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019 

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Cell MedX Corp.
Date: October 15, 2019	By:	/s/ Frank McEnulty
		Frank McEnulty
		Chief Executive Officer and Director
		(Principal Executive Officer)
Date: October 15, 2019	By:	/s/Yanika Silina
		Yanika Silina
		Chief Financial Officer and Director
		(Principal Accounting Officer)

25

EX-31.1

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Frank McEnulty, certify that:

1.   I have reviewed this Quarterly Report on Form 10-Q for the period ending August 31, 2019, of Cell MedX Corp.;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  October 15, 2019

/s/ Frank McEnulty

Frank McEnulty

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Yanika Silina, certify that:

1.   I have reviewed this Quarterly Report on Form 10-Q for the period ending August 31, 2019, of Cell MedX Corp.;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:  October 15, 2019

/s/ Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)

EX-32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending August 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 15, 2019

/s/ Frank McEnulty

Frank McEnulty

Chief Executive Officer

(Principal Executive Officer)

EX-32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending August 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 15, 2019

/s/Yanika Silina

Yanika Silina

Chief Financial Officer

(Principal Accounting Officer)

XML

Inventory Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Inventory Disclosure

NOTE 3 - INVENTORY

As at August 31, 2019, the inventory consisted of eBalance devices held for sale valued at $16,733 (May 31, 2019 - $24,505) and work in progress, that included unfinished eBalance devices and supplies required for manufacturing valued at $53,553 (May 31, 2019 - $48,696).

The cost of eBalance devices used for further research and development and for in-house observational trials are recognized as part of research and development expenses. During the three-month period ended August 31, 2019, the Company recognized $3,712 as cost of eBalance devices used in research and development. The cost of eBalance devices used in marketing and advertising are recognized as part of general and administrative expenses. During the three-month period ended August 31, 2019, the Company recognized $3,712 as cost of eBalance devices used for marketing and advertising purposes.

XML

Document and Entity Information - shares	3 Months Ended
	Aug. 31, 2019	Oct. 15, 2019
Details
Registrant CIK	0001493712
Fiscal Year End	--05-31
Registrant Name	Cell MedX Corp.
SEC Form	10-Q
Period End date	Aug. 31, 2019
Tax Identification Number (TIN)	38-3939625
Number of common stock shares outstanding		55,815,709
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Entity File Number	000-54500
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	123 W. Nye Ln, Suite 446
Entity Address, City or Town	Carson City
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89706
City Area Code	844
Local Phone Number	238-2692
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Document Quarterly Report	true
Document Transition Report	false

XML

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Share Issuance Obligation	Additional Paid-in Capital	Reserves	Retained Earnings	AOCI Attributable to Parent	Total
Equity Balance at May. 31, 2018	$ 44,283	$ 0	$ 4,916,201	$ 14,400	$ (6,050,841)	$ 2,539	$ (1,073,418)
Equity Balance, Shares at May. 31, 2018	44,282,749
Net income (loss) for the period	$ 0	0	0	0	(243,465)	0	(243,465)
Translation to reporting currency	$ 0	0	0	0	0	869	869
Equity Balance, Shares at Aug. 31, 2018	44,282,749
Equity Balance at Aug. 31, 2018	$ 44,283	0	4,916,201	14,400	(6,294,306)	3,408	(1,316,014)
Warrants issued for debt	0	0	193,665	0	0	0	193,665
Net income (loss) for the period	0	0	0	0	(662,516)	0	(662,516)
Translation to reporting currency	$ 0	0	0	0	0	12,306	12,306
Equity Balance, Shares at May. 31, 2019	44,282,749
Equity Balance at May. 31, 2019	$ 44,283	0	5,109,866	14,400	(6,956,822)	15,714	(1,772,559)
Stock issued for cash, value	$ 4,050	0	481,950	0	0	0	486,000
Stock issued for cash, shares	4,050,000
Shares to be issued on exercise of warrants	$ 0	374,148	0	0	0	0	374,148
Net income (loss) for the period	0	0	0	0	(245,287)	0	(245,287)
Translation to reporting currency	$ 0	0	0	0	0	(6,941)	(6,941)
Equity Balance, Shares at Aug. 31, 2019	48,332,749
Equity Balance at Aug. 31, 2019	$ 48,333	$ 374,148	$ 5,591,816	$ 14,400	$ (7,202,109)	$ 8,773	$ (1,164,639)

XML

Unearned Revenue Disclosure (Details) - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Revenues	$ 20,301	$ 0
Distribution rights
Revenues	$ 8,958	$ 0

XML

Inventory Disclosure (Details) - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	May 31, 2019
Inventory	$ 70,286		$ 73,201
Research and development costs	60,713	$ 149,734
General and administrative expenses	86,562	$ 27,242
Devices held for resale
Inventory	16,733		24,505
Work in progress, including unfinished eBalance devices and supplies
Inventory	53,553		$ 48,696
eBalance Devices
Research and development costs	3,712
General and administrative expenses	$ 3,712

XML

Share Capital Disclosure: Schedule of Stock Option Activity (Details) - $ / shares			12 Months Ended
	Aug. 31, 2019	May 31, 2019	May 31, 2019	May 31, 2018
Details
Stock options outstanding				9,450,000
Options outsanding, weighted average exercise price	$ 0.24	$ 0.24	$ 0.24	$ 0.35
Options cancelled	7,050,000	7,050,000	(2,400,000)

XML

Unearned Revenue Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Unearned Revenue Disclosure

NOTE 6 - UNEARNED REVENUE

Changes to the unearned revenue as at August 31, 2019 and May 31, 2019:

	August 31, 2019		May 31, 2019
Unearned revenue, beginning of the period	$	307,742	$	51,585
Deposits to distribution rights		25,000		250,000
Security deposits received from/(refunded to) customers		(2,269)		6,806
Security deposits recognized in sales		(4,537)		-
Non-refundable deposit on distribution rights		(8,958)		-
Foreign exchange		346		(649)
Unearned revenue, end of the period	$	317,324	$	307,742

During the three-month period ended August 31, 2019, the Company entered into a letter of intent for the wholesale distribution rights to all Mainlined China, not including Hong Kong (the “LOI”). As part of the LOI the potential distributor (the “Distributor”) paid a non-refundable fee of $25,000. The LOI’s term is 240 days, in which for the first 120 days the Distributor will be permitted to test the eBalance devices (the “Testing Period”). During the Testing Period, the Company agreed not to enter into any agreements for the wholesale rights to Mainland China.

The Company amortizes the non-refundable deposit received from the Distributor on a straight-line basis over the full length of the LOI. As at August 31, 2019, $8,958 were recorded as revenue from distribution rights (Note 7).

XML

Subsequent Event Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Subsequent Event Disclosure

NOTE 10 - SUBSEQUENT EVENTS

Subsequent to August 31, 2019, the Company received $167,150 under convertible notes payable which bear interest at 6% per annum compounded monthly. At the discretion of the lenders, the balance of the note payable may be converted to shares of the Company’s common stock at the price of then current private placement financing.

Subsequent to August 31, 2019, the Company paid $42,500 for promotional and investor relations activities aimed to increase awareness about the Company within the investment community.

XML

Organization and Nature of Operations: Going Concern (Details) - USD ($)	Aug. 31, 2019	May 31, 2019
Details
Accumulated deficit	$ 7,202,109	$ 6,956,822

XML

Equipment Disclosure: Amortization schedule for the equipment (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Amortization schedule for the equipment

	August 31, 2019		May 31, 2019
Book value, beginning of the period	$	1,281	$	-
Changes during the period		2,463		1,915
Amortization		(268)		(580)
Foreign exchange		21		(54)
Book value, end of the period	$	3,497	$	1,281

XML

Share Capital Disclosure: Schedule of Stock Option Activity (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Stock Option Activity

	Three months ended August 31, 2019			Year ended May 31, 2019
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	7,050,000	$	0.24	9,450,000	$	0.35
Options cancelled	--	$	n/a	(2,400,000)	$	0.67
Options outstanding, ending	7,050,000	$	0.24	7,050,000	$	0.24

XML

Share Capital Disclosure: Schedule of Warrant Activity (Details) - shares	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	May 31, 2019	May 31, 2018
Details
Number of warrants outstanding	16,864,605		20,297,565	12,814,605
Warrants issued	4,050,000	7,482,960
Warrants exercised	(7,482,960)

XML

Unearned Revenue Disclosure: Changes to Unearned Revenue (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Changes to Unearned Revenue

	August 31, 2019		May 31, 2019
Unearned revenue, beginning of the period	$	307,742	$	51,585
Deposits to distribution rights		25,000		250,000
Security deposits received from/(refunded to) customers		(2,269)		6,806
Security deposits recognized in sales		(4,537)		-
Non-refundable deposit on distribution rights		(8,958)		-
Foreign exchange		346		(649)
Unearned revenue, end of the period	$	317,324	$	307,742

XML

Share Capital Disclosure: Schedule of Stock Options Outstanding (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Stock Options Outstanding

Exercise price	Grant date	Number of options Outstanding and exercisable
$0.05	November 25, 2014	2,500,000
$0.35	August 5, 2015	2,500,000
$0.35	August 24, 2017	2,050,000
$0.24		7,050,000

XML

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) - USD ($)	Aug. 31, 2019	May 31, 2019
Due to related parties	$ 235,314	$ 383,688
Due to the former CEO and director
Due to related parties	0	51,746
Due to the CEO
Due to related parties	86,400	75,600
Due to CFO
Due to related parties	25,002	33,507
Due to VP of Technology and Operations
Due to related parties	37,142	54,999
Due to former Chief Medical Officer
Due to related parties	0	81,059
Due to former VP of Corporate Strategy
Due to related parties	$ 86,770	$ 86,777

XML

Share Capital Disclosure: Schedule of Stock Options Outstanding (Details) - $ / shares	3 Months Ended	12 Months Ended
	Aug. 31, 2018	May 31, 2016	May 31, 2015
Granted Nov 25 2014
Exercise price (options)			$ 0.05
Stock options granted			2,500,000
Granted Aug 5 2015
Exercise price (options)		$ 0.35
Stock options granted		2,500,000
Granted Aug 24 2017
Exercise price (options)	$ 0.35
Stock options granted	2,050,000

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Revenue
Revenues	$ 20,301	$ 0
Cost of goods sold	(5,375)	0
Gross margin	14,926	0
Operating expenses
Amortization	268	0
Consulting fees	89,271	63,960
Distribution expenses	16,447	0
General and administrative expenses	86,562	27,242
Research and development costs	60,713	149,734
Total operating expenses	253,261	240,936
Other items
Financing costs	0	(387)
Interest	(6,952)	(2,142)
Net loss	(245,287)	(243,465)
Unrealized foreign exchange gain (loss)	(6,941)	869
Comprehensive loss	$ (252,228)	$ (242,596)
Earnings Per Share, Basic and Diluted	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding, Basic and Diluted	47,245,792	44,282,749
Sales
Revenue
Revenues	$ 11,343	$ 0
Distribution rights
Revenue
Revenues	$ 8,958	$ 0

XML

Related Party Transactions Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Related Party Transactions Disclosure

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than notes payable to related parties (Note 8) at August 31, 2019 and at May 31, 2019:

	August 31, 2019		May 31, 2019
Due to the former Chief Executive Officer (“CEO”) and director (1)	$	-	$	51,746
Due to the CEO		86,400		75,600
Due to the Chief Financial Officer (“CFO”)		25,002		33,507
Due to the Vice President (“VP”), Technology and Operations		37,142		54,999
Due to the former Chief Medical Officer(1)		-		81,059
Due to the former VP, Corporate Strategy and major shareholder		86,770		86,777
Due to related parties	$	235,314	$	383,688

(1)           The amounts due to former CEO and former Chief Medical Officer have been reclassified to accounts payable, as both persons were not related to the Company as at August 31, 2019.

The amounts due to related parties are unsecured, due on demand and bear no interest.

During the three-month periods ended August 31, 2019 and 2018, the Company had the following transactions with related parties:

	August 31, 2019		August 31, 2018
Management fees incurred to the CEO	$	10,800	$	10,800
Management fees incurred to the CFO		3,000		3,000
Consulting fees incurred to the VP, Technology and Operations		11,271		11,460
Interest accrued on loans from significant shareholder (Note 8)		6,477		2,048
Total transactions with related parties	$	31,548	$	27,308

XML

Notes and Advances Payable Disclosure (Details) - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	May 31, 2019
Notes and advances payable	$ 162,374		$ 511,754
Advances payable	15,000	$ 28,871
Interest expense	6,952	$ 2,142
Loans with arms-length party
Notes and advances payable	31,571		30,678
Mr. Jeffs Loans Payable
Notes and advances payable	6,874
Unsecured Line of Credit with Related Party
Notes and advances payable	35,623
Advances Payable
Notes and advances payable	$ 88,306		$ 73,048

XML

Unearned Revenue Disclosure: Changes to Unearned Revenue (Details) - USD ($)	Aug. 31, 2019	May 31, 2019
Unearned revenue	$ 317,324	$ 307,742
Deposits to distribution rights
Changes to unearned revenue	25,000	250,000
Security deposits received from/(refunded to) customers
Changes to unearned revenue	(2,269)	6,806
Security deposits recognized in sales
Changes to unearned revenue	(4,537)	0
Non-refundable deposit on distribution rights
Changes to unearned revenue	(8,958)	0
Foreign exchange effects
Changes to unearned revenue	$ 346	$ (649)

XML

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Management fees incurred the CEO
Transactions with related parties	$ 10,800	$ 10,800
Management fees incurred to the CFO
Transactions with related parties	3,000	3,000
Consulting fees incurred to the VP of Technology and Operations
Transactions with related parties	11,271	11,460
Interest accrued on shareholder loans
Transactions with related parties	$ 6,477	$ 2,048

XML

Revenue Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Revenue Disclosure

NOTE 7 - REVENUE

During the three-month period ended August 31, 2019, the Company’s revenue consisted of sales of its eBalance devices to end-users and sale of rights to the wholesale distribution of eBalance devices. Following are the details of revenue and associated costs:

	Three months ended August 31, 2019
Sales of eBalance devices	$	11,343
Cost of eBalance devices		(4,052)
Royalty payable		(1,323)
Distribution rights (Note 6)		8,958
Gross margin	$	14,926

XML

Organization and Nature of Operations: Going Concern (Policies)

3 Months Ended

Aug. 31, 2019

Policies

Going Concern

Going concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of August 31, 2019, the Company has not achieved profitable operations and has accumulated a deficit of $7,202,109. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

XML

Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Short-term Loans and Advances Outstanding

As at August 31, 2019
Principal Outstanding		Interest Rate per Annum		Accrued Interest(5)		Total Book Value
$	29,468	6%	Non-convertible(1)	$	2,103	$	31,571
	6,870	6%	Related party(2)		4		6,874
	35,606	6%	Related party(2),(3)		17		35,623
	88,306	0%	Advances(4)		--		88,306
$	160,250			$	2,124	$	162,374
As at May 31, 2019
Principal Outstanding		Interest Rate per Annum		Accrued Interest(5)		Total Book Value
$	29,065	6%	Non-convertible(1)	$	1,613	$	30,678
	114,027	0%-12%	Related party(2)		12,533		126,560
	275,000	6%	Related party(2),(3)		6,468		281,468
	73,048	0%	Advances(4)		--		73,048
$	491,140			$	20,614	$	511,754

XML

Share Capital Disclosure: Schedule of Warrant Details (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Warrant Details

Exercise price	Grant Date	Number of warrants exercisable
$0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021	March 3, 2016	2,000,000
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021	October 12, 2016	9,094,605
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020	October 12, 2017	1,480,000
$1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021	February 7, 2018	240,000
$0.20 expiring on June 24, 2021	June 24, 2019	3,950,000
$0.20 expiring on July 22, 2021	July 22, 2019	100,000
		16,864,605

XML

Share Capital Disclosure: Schedule of Warrant Details (Details)	Aug. 31, 2019 shares
Number of warrants exercisable	16,864,605
Warrants Granted Mar 3 2016
Number of warrants exercisable	2,000,000
Warrants Granted Oct 12 2016
Number of warrants exercisable	9,094,605
Warrants Granted Oct 12 2017
Number of warrants exercisable	1,480,000
Warrants Granted Feb 7 2018
Number of warrants exercisable	240,000
Warrants Granted June 24 2019
Number of warrants exercisable	3,950,000
Warrants Granted July 22 2019
Number of warrants exercisable	100,000

XML

CONSOLIDATED BALANCE SHEETS - USD ($)	Aug. 31, 2019	May 31, 2019
Current assets
Cash	$ 352,671	$ 57,172
Inventory	70,286	73,201
Other current assets	23,858	58,887
Total current assets	446,815	189,260
Equipment	3,497	1,281
Total assets	450,312	190,541
Liabilities
Accounts payable	866,904	734,281
Accrued liabilities	33,035	25,635
Due to related parties	235,314	383,688
Notes and advances payable	162,374	511,754
Unearned revenue	317,324	307,742
Total liabilities	1,614,951	1,963,100
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 48,332,749 and 44,282,749 shares issued and outstanding at August 31, 2019 and at May 31, 2019, respectively	48,333	44,283
Additional paid-in capital	5,591,816	5,109,866
Obligation to issue shares	374,148	0
Reserves	14,400	14,400
Accumulated deficit	(7,202,109)	(6,956,822)
Accumulated other comprehensive income	8,773	15,714
Total stockholders' deficit	(1,164,639)	(1,772,559)
Total liabilities and stockholders' deficit	$ 450,312	$ 190,541

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Cash flows used in operating activities
Net loss	$ (245,287)	$ (243,465)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable	6,952	2,142
Amortization	268	0
Financing fees - non-cash	0	387
Unrealized foreign exchange	(2,905)	394
Changes in operating assets and liabilities
Inventory:	4,215	(3,238)
Other current assets:	33,295	1,843
Accounts payable:	(3,617)	177,333
Accrued liabilities:	7,400	2,900
Unearned revenue:	9,236	0
Due to related parties:	(13,239)	15,120
Net cash flows used in operating activities	(203,682)	(46,584)
Cash flows used in investing activities
Acquisition of equipment	(2,463)	0
Net cash used in investing activities	(2,463)	0
Cash flows from financing activities
Advances payable	15,000	28,871
Proceeds from notes payable	0	23,029
Proceeds from subscription to shares	486,000	0
Net cash provided by financing activities	501,000	51,900
Effects of foreign currency exchange on cash	644	167
Increase in cash	295,499	5,483
Cash, beginning	57,172	8,200
Cash, ending	352,671	13,683
Non-cash financing transactions:
Proceeds from exercise of warrants for debt	$ 374,148	$ 0

XML

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Transactions with Related Parties

	August 31, 2019		August 31, 2018
Management fees incurred to the CEO	$	10,800	$	10,800
Management fees incurred to the CFO		3,000		3,000
Consulting fees incurred to the VP, Technology and Operations		11,271		11,460
Interest accrued on loans from significant shareholder (Note 8)		6,477		2,048
Total transactions with related parties	$	31,548	$	27,308

XML

Equipment Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Equipment Disclosure

NOTE 5 - EQUIPMENT

Changes in the net book value of the equipment at August 31, 2019 and May 31, 2019 are as follows:

	August 31, 2019		May 31, 2019
Book value, beginning of the period	$	1,281	$	-
Changes during the period		2,463		1,915
Amortization		(268)		(580)
Foreign exchange		21		(54)
Book value, end of the period	$	3,497	$	1,281

XML

Share Capital Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Share Capital Disclosure

NOTE 9 - SHARE CAPITAL

On May 30, 2019, the Company announced a non-brokered private placement offering (the “2019 Offering”) set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of up to $750,000. Each Unit sold under the 2019 Offering was to consist of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on the second year anniversary of the date of issuance of the Warrant. Each Warrant will be exercisable into one share of the Company’s common stock at $0.20 per share.

On June 24, 2019, the Company closed the first tranche of its 2019 Offering by issuing 3,950,000 Units for total gross proceeds of $474,000. On July 22, 2019 the Company closed the second tranche of the 2019 Offering by issuing 100,000 Units for total gross proceeds of $12,000

Options

The changes in the number of stock options outstanding during the three-month period ended August 31, 2019 and for the year ended May 31, 2019 are as follows:

	Three months ended August 31, 2019			Year ended May 31, 2019
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	7,050,000	$	0.24	9,450,000	$	0.35
Options cancelled	--	$	n/a	(2,400,000)	$	0.67
Options outstanding, ending	7,050,000	$	0.24	7,050,000	$	0.24

Details of options outstanding and exercisable as at August 31, 2019, are as follows:

Exercise price	Grant date	Number of options Outstanding and exercisable
$0.05	November 25, 2014	2,500,000
$0.35	August 5, 2015	2,500,000
$0.35	August 24, 2017	2,050,000
$0.24		7,050,000

At August 31, 2019, the weighted average remaining contractual life of the stock options outstanding was 1.55 years.

Warrants

The changes in the number of warrants outstanding during the three-month period ended August 31, 2019 and for the year ended May 31, 2019 are as follows:

	Three months ended August 31, 2019	Year ended May 31, 2019
Warrants outstanding, beginning	20,297,565	12,814,605
Warrants issued	4,050,000	7,482,960
Warrants exercised	(7,482,960)	--
Warrants outstanding, ending	16,864,605	20,297,565

Details of warrants outstanding as at August 31, 2019, are as follows:

Exercise price	Grant Date	Number of warrants exercisable
$0.60 during the period from March 3, 2019 to March 3, 2020 $0.75 during the period from March 3, 2020 to March 3, 2021	March 3, 2016	2,000,000
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.25 during the period from October 12, 2019 to October 12, 2020 $1.50 during the period from October 12, 2020 to October 12, 2021	October 12, 2016	9,094,605
$1.00 during the period from October 12, 2018 to October 12, 2019 $1.50 during the period from October 12, 2019 to October 12, 2020	October 12, 2017	1,480,000
$1.00 during the period from February 7, 2019 to February 7, 2020 $1.50 during the period from February 7, 2020 to February 7, 2021	February 7, 2018	240,000
$0.20 expiring on June 24, 2021	June 24, 2019	3,950,000
$0.20 expiring on July 22, 2021	July 22, 2019	100,000
		16,864,605

At August 31, 2019, the weighted average life and exercise price of the warrants was 1.86 years and $0.76, respectively.

XML

Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) - USD ($)	3 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Cost of goods sold	$ (5,375)	$ 0
Revenues	20,301	0
Gross margin	14,926	0
Cost of eBalance devices
Cost of goods sold	(4,052)
Royalty payable for eBalance devices
Cost of goods sold	(1,323)
Distribution rights
Revenues	$ 8,958	$ 0

XML

Other Current Assets Disclosure (Details) - USD ($)	Aug. 31, 2019	May 31, 2019
Other current assets	$ 23,858	$ 58,887
Prepaid expenses
Other current assets	13,419	50,331
Receivables associated with GST Cell MedX Canada
Other current assets	$ 10,439	$ 8,556

XML

CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Aug. 31, 2019	May 31, 2019
Details
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued	48,332,749	44,282,749

XML

Organization and Nature of Operations

3 Months Ended

Aug. 31, 2019

Notes

Organization and Nature of Operations

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness.

Unaudited Interim Financial Statements

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2019, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 6, 2019. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended August 31, 2019, are not necessarily indicative of the results that may be expected for the year ending May 31, 2020.

Going concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared assuming the Company will continue as a going concern. As of August 31, 2019, the Company has not achieved profitable operations and has accumulated a deficit of $7,202,109. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

Recent accounting pronouncements

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2016-02,“Leases” (“ASU 2016-02”). ASU 2016-02 changes current U.S. GAAP for lessees to recognize lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods. Early application is permitted. The Company adopted the ASU 2016-02 on June 1, 2019, and is currently assessing the impact that the adoption will have on future financial statements and disclosures, since as of the date of these financial statements, the Company has no leasing arrangements. However, the Company is evaluating a possible impact ASU 2016-02 may have on the Company’s decision to introduce leasing options for its eBalance devices.

XML

Other Current Assets Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Other Current Assets Disclosure

NOTE 4 - OTHER CURRENT ASSETS

As at August 31, 2019, other current assets consisted of $13,419 in prepaid expenses (May 31, 2019 - $50,331) and $10,439 in receivables associated with GST Cell MedX Canada paid on the taxable supplies (May 31, 2019 - $8,556).

XML

Notes and Advances Payable Disclosure

3 Months Ended

Aug. 31, 2019

Notes

Notes and Advances Payable Disclosure

NOTE 8 - NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at August 31, 2019 and May 31, 2019:

As at August 31, 2019
Principal Outstanding		Interest Rate per Annum		Accrued Interest(5)		Total Book Value
$	29,468	6%	Non-convertible(1)	$	2,103	$	31,571
	6,870	6%	Related party(2)		4		6,874
	35,606	6%	Related party(2),(3)		17		35,623
	88,306	0%	Advances(4)		--		88,306
$	160,250			$	2,124	$	162,374
As at May 31, 2019
Principal Outstanding		Interest Rate per Annum		Accrued Interest(5)		Total Book Value
$	29,065	6%	Non-convertible(1)	$	1,613	$	30,678
	114,027	0%-12%	Related party(2)		12,533		126,560
	275,000	6%	Related party(2),(3)		6,468		281,468
	73,048	0%	Advances(4)		--		73,048
$	491,140			$	20,614	$	511,754

(1) Loans Payable

As at August 31, 2019, the Company owed a total of $31,571 (2019 - $30,678) under two separate loan agreements. Both loans bear interest at 6% per annum compounded monthly, are unsecured, and payable on demand.

(2) Related Party Loans Payable

On August 28, 2019, Mr. Jeffs, the Company’s major shareholder, exercised 2,482,960 warrants to acquire 2,482,960 shares of the Company granted in consideration for the funds Mr. Jeffs advanced to the Company during its fiscal 2019 and 2018 years.  To exercise the warrants, Mr. Jeffs chose to apply $124,148, the Company owed under the demand notes payable against the purchase price of the shares (Note 9). The exercise price was first applied to $15,051 (CAD$20,019) in interest accrued on the notes payable, with the remaining $109,097 (CAD$145,110) applied to principal. The shares were issued on September 9, 2019. As at August 31, 2019, the Company owed Mr. Jeffs $6,874 under the remaining note payable, which continues to accumulate interest at 6% per annum compounded monthly.

(3) Unsecured Line of Credit with Related Party

On August 28, 2019, Mr. Jeffs exercised 5,000,000 warrants to acquire 5,000,000 shares of the Company granted to Mr. Jeffs in consideration for an unsecured line of credit of up to $250,000 (the “Credit Line”) dated for reference December 27, 2018. To exercise the warrant, Mr. Jeffs chose to apply $250,000, the Company owed under the Credit Line against the purchase price of the shares (Note 9). The exercise price was first applied to $10,606 in interest accrued on the balance due under the Credit Line, $25,000 was applied towards the Credit Line set-up fee, and the remaining $214,394 was applied to principal. The shares were issued on September 9, 2019. As at August 31, 2019, the Company owed Mr. Jeffs $35,623 under the Credit Line, which continues to accumulate interest at 6% per annum compounded monthly.

(4) Advances Payable

During the three-month period ended August 31, 2019, the Company borrowed $15,000. The advances are non-interest bearing, unsecured and payable on demand. As at August 31, 2019, a total of $88,306 (2019 - $73,048) was due and payable on account of the advances.

(5) Interest Expense

During the three-month period ended August 31, 2019, the Company recorded $6,952 (2019 - $2,142) in interest expense associated with its liabilities under the notes and advances payable, of which $2,321 (2019 - $2,048) was accrued on the loans received from Mr. Jeffs, and $4,156 (2019 - $Nil) in interest accrued on the Line of Credit.

XML

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Amounts Due to Related Parties

	August 31, 2019		May 31, 2019
Due to the former Chief Executive Officer (“CEO”) and director (1)	$	-	$	51,746
Due to the CEO		86,400		75,600
Due to the Chief Financial Officer (“CFO”)		25,002		33,507
Due to the Vice President (“VP”), Technology and Operations		37,142		54,999
Due to the former Chief Medical Officer(1)		-		81,059
Due to the former VP, Corporate Strategy and major shareholder		86,770		86,777
Due to related parties	$	235,314	$	383,688

XML

Notes and Advances Payable Disclosure: Schedule of Short-term Loans and Advances Outstanding (Details) - USD ($)	Aug. 31, 2019	May 31, 2019
Principal outstanding	$ 160,250	$ 491,140
Accrued interest/accretion	2,124	20,614
Notes and advances payable	162,374	511,754
Short-term Loan 1
Principal outstanding	$ 29,468	$ 29,065
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 2,103	$ 1,613
Notes and advances payable	31,571	30,678
Short-term Loan 2
Principal outstanding	$ 6,870	$ 114,027
Effective interest rate	6.00%	12.00%
Accrued interest/accretion	$ 4	$ 12,533
Notes and advances payable	6,874	126,560
Short-term Loan 3
Principal outstanding	$ 35,606	$ 275,000
Effective interest rate	6.00%	6.00%
Accrued interest/accretion	$ 17	$ 6,468
Notes and advances payable	35,623	281,468
Short-term Loan 4
Principal outstanding	$ 88,306	$ 73,048
Effective interest rate	0.00%	0.00%
Notes and advances payable	$ 88,306	$ 73,048

XML

Equipment Disclosure: Amortization schedule for the equipment (Details) - USD ($)	3 Months Ended	12 Months Ended
	Aug. 31, 2019	May 31, 2019
Details
Increase (decrease) in equipment	$ 2,463	$ 1,915
Amortization	(268)	(580)
Foreign exchange gain (loss), equipment	21	(54)
Equipment, book value	$ 3,497	$ 1,281

XML

Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Revenue and Associated Costs

	Three months ended August 31, 2019
Sales of eBalance devices	$	11,343
Cost of eBalance devices		(4,052)
Royalty payable		(1,323)
Distribution rights (Note 6)		8,958
Gross margin	$	14,926

XML

Share Capital Disclosure: Schedule of Warrant Activity (Tables)

3 Months Ended

Aug. 31, 2019

Tables/Schedules

Schedule of Warrant Activity

	Three months ended August 31, 2019	Year ended May 31, 2019
Warrants outstanding, beginning	20,297,565	12,814,605
Warrants issued	4,050,000	7,482,960
Warrants exercised	(7,482,960)	--
Warrants outstanding, ending	16,864,605	20,297,565

XML

Subsequent Event Disclosure (Details) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 15, 2019	Aug. 31, 2019	Aug. 31, 2018
Proceeds from notes payable		$ 0	$ 23,029
Promotional and investor relations expenses	$ 42,500
From Convertible Notes Payable
Proceeds from notes payable	$ 167,150